Microbot Medical 5/15/2024 Earnings Report

Microbot Medical EPS Results

• Actual EPS: -$0.17
• Consensus EPS: -$0.17
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Microbot Medical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Microbot Medical Announcement Details

• Date: 5/15/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Microbot Medical (NASDAQ:MBOT), a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.